Nuvectra Corporation (NVTR) Reports Q2 Loss of $0.85/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Nuvectra Reports Second Quarter 2016 Financial Results
August 10, 2016 4:01 PM EDTPLANO, Texas, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the second quarter ended July 1, 2016.
Recent Accomplishments & Highlights
U.S. sales team now has 28 active territories with approximately 10 territories scheduled to complete training by the end of AugustInitiated U.S. sales of Algovita® Spinal Cord Stimulation SystemEstablished Medical Advisory Board with industry leading physicians to guide clinical and commercial activityEntered into license agreement with Aleva Neurotherapeutics, S.A. to develop Nuvectras neurostimulation... More